Teriparatide and Osseous Regeneration in the Oral Cavity | Zendy

Jill D. Bashutski | Zendy; Robert Eber | Zendy; Janet S. Kinney | Zendy; Erika Benavides | Zendy; Samopriyo Maitra | Zendy; Thomas M. Braun | Zendy; William V. Giannobile | Zendy; Laurie K. McCauley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Teriparatide and Osseous Regeneration in the Oral Cavity

Author(s) -

Jill D. Bashutski,

Robert Eber,

Janet S. Kinney,

Erika Benavides,

Samopriyo Maitra,

Thomas M. Braun,

William V. Giannobile,

Laurie K. McCauley

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1005361

Subject(s) - teriparatide , medicine , osteoporosis , parathyroid hormone , anabolism , bone formation , oral cavity , regeneration (biology) , bone density conservation agents , surgery , dentistry , bone density , calcium , bone mineral , biology , microbiology and biotechnology

Intermittent administration of teriparatide, a drug composed of the first 34 amino acids of parathyroid hormone, has anabolic effects on bone. Although teriparatide has been evaluated for the treatment of osteoporosis and for the healing of fractures, clinical trials evaluating it for the treatment of osseous conditions of the oral cavity in humans are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research